

Agenda

MOC na ASCO 2023



SISTEMA NERVOSO CENTRAL

Camilla Akemi Felizardo Yamada



- Formada pela Universidade Estadual de Maringá, atua na área de Oncologia Clínica.
- Titular na Oncologia Clínica da BP - A Beneficência Portuguesa de São Paulo. Membro do Comitê Técnico Científico do SNC da Sociedade Brasileira de Oncologia Clínica.
- Membro da Sociedade de Neuro-oncologia da América Latina.
- *Chair LACOG Neuro-oncologia.*
- CRM 118.900.



Conflitos de Interesse


MOC na ASCO 2023

De acordo com a Norma 1595/2000 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro:


- Participo de estudos clínicos patrocinados pelas empresas: Roche, AstraZeneca, MSD.
- Palestrante convidado: Jansen, Bayer, BMS, Daiichi-Sankyo, Dr. Reddys.
- Patrocínio para Congressos/Eventos: Jansen, Bayer, AstraZeneca, Daiichi-Sankyo.
- Não possuo ações de quaisquer companhias farmacêuticas.



- *INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.*
- Presenter: Ingo K. Mellinghoff, MD, FACP | Memorial Sloan Kettering Cancer Center
- *Abstract: LBA1*
- **Vorasidenibe: Pan-inibidor IDH1 e IDH2, potente, reversível e com penetração em SNC.**



- É uma mutação inicial na oncogênese dos gliomas difusos.




- NAPH protege contra estresse oxidativo e consequente dano do DNA.
- Acumulo D2HG leva a alterações epigenéticas, promovendo a tumorigênese.

Figura 1: Algoritmo com achados histológicos e moleculares nos gliomas IDH mutantes de acordo com CNS5.



INDIGO trial

- Fase III, multicêntrico, randomizado, duplo-cego.



Sistema Nervoso Central



MOC na ASCO 2023

Oral abstract session

- ***A phase II study analyzing pre-operative stereotactic radiosurgery followed by resection for patients with 1-4 brain metastases.***
- Presenter: Namita Agrawal, MD | Department of Radiation Oncology, Simon Cancer Center, Indiana University School of Medicine
- *Abstract: 2003*

Sistema Nervoso Central



MOC na ASCO 2023

Oral abstract session

- ***Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.***
- Presenter: Antoine F Carpentier | Hôpital Saint-Louis
- ***Abstract: 2005***

Sistema Nervoso Central



MOC na ASCO 2023

Oral abstract session

- ***Belzutifan treatment for von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.***
- Presenter: Othon Iliopoulos, MD | Massachusetts General Hospital Cancer Center and Harvard Medical School
- ***Abstract: 2008***

Sistema Nervoso Central



MOC na ASCO 2023

Poster discussion

- ***Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).***
- Presenter: Michael Weller, MD | Department of Neurology, University Hospital and University of Zurich
- *Abstract: 2016*
- Poster Bd #: 373

Sistema Nervoso Central



MOC na ASCO 2023

Poster discussion

- ***RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) Criteria for high- and low-grade gliomas in adults.***
- Presenter: Patrick Y. Wen, MD | Dana-Farber Cancer Institute
- ***Abstract: 2017***
- Poster Bd #: 374

Sistema Nervoso Central



MOC na ASCO 2023

Poster discussion

- *A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.*
- Presenter: Paul James Mulholland, PhD, MBBS | University College Hospital-London
- *Abstract: LBA2023*
- Poster Bd #: 380

Sistema Nervoso Central



MOC na ASCO 2023

Poster discussion

- ***Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.***
- Presenter: David D. Tran, MD, PhD | Department of Neurological Surgery, Norris Comprehensive Cancer Center, University of Southern California
- ***Abstract: 2024***
- Poster Bd #: 381

Créditos

MOC na ASCO 2023 © 2023 MOC - Manual de Oncologia Clínica do Brasil. Todos os direitos reservados. São Paulo, SP.
Proibida a reprodução total ou parcial do conteúdo e imagens sem a permissão dos titulares de seus direitos autorais.

Apoio educacional:

